EMD Serono, Canada launches trymester™ , a one-of-a-kind app to support Canadian couples with infertility Français
MISSISSAUGA, ON, Aug. 14, 2015 /CNW/ - Today, EMD Serono, a division of EMD Inc., Canada, a subsidiary of Merck KGaA, Darmstadt, Germany, announces the launch of trymester™, a one-of-a-kind fertility app designed to empower Canadians to learn more about their fertility. trymester™ is now exclusively available for the iPad in the App Store in Canada.
"About 1 in 6 couples in Canada of child bearing age will need to seek medical support to address their fertility1," said Rehan Verjee, Managing Director, EMD Serono, Canada. "That's why we are excited to provide couples with access to an app that will support them and enable them to better understand how to get closer to their dream of building a family."
trymester™ is an interactive app designed in collaboration with a multidisciplinary group of fertility experts. It provides users with detailed Canadian information about fertility and conception and also information to support couples looking to address their infertility. The application includes an ovulation tracker, digital referral form, a clinic locator, and a journal to support couples as they learn more about their fertility and the options that are available to them in Canada.
"The choice to start a family is already an emotional experience when you are dealing with infertility. The worry and anxiety can be overwhelming when there are a number of considerations to factor into the decision," says Dr. Judith Perry, a family physician and fertility expert in Toronto. "There is a lot to keep track of from cycles to appointments and clinic information, so having that information validated by the experts and available in one easily accessible tool can help ease the stress."
The trymester™ app is available for download on the iPad for free from the App Store. Follow the trymester™ app on Twitter @TrymesterApp.
About EMD Serono, Canada
EMD Serono is a Division of EMD Inc., Canada, a subsidiary of Merck KGaA, Darmstadt, Germany. In Canada, EMD Serono provides innovative drug therapies that address unmet medical needs in the areas of neurodegenerative diseases, fertility and endocrinology. EMD Serono employs approximately 150 people across Canada and is headquartered in Mississauga, Ontario. For more information, please visit to www.emdserono.ca
About Merck Serono
Merck Serono is the biopharmaceutical business of Merck KGaA, Darmstadt, Germany. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.
Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.
For more information, please visit www.merckserono.com.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck KGaA, Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany, holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
SOURCE EMD Serono
Priya Ramsingh, 905-919-0200 ext. 5256
Share this article